VIKING THERAPEUTICS INC

Viking Therapeutics rockets past rivals with breakthrough VK2735 data and a $500 M capital raise, positioning it as a new force in the $100 B obesity‑drug market.

Explore Viking Therapeutics: a La Jolla‑based biotech focused on metabolic & endocrine drugs poised to thrive as the pharma sector shifts toward personalized, innovative therapies.

Viking Therapeutics Q2 earnings preview: investors watch for guidance shifts amid ongoing losses and a volatile stock—what a turnaround could mean.

Viking Therapeutics Q1 2026: $603M cash, robust pipeline with phase‑3 dual‑agonist VK2735, and new amylin drug, poised to reshape obesity treatment while managing R&D losses.

Viking Therapeutics completes enrollment for Phase 3 VANQUISH‑2, a 78‑week trial of its dual GLP‑1/GIP agonist VK2735 for type 2 diabetes and obesity, promising new weight‑loss therapy.

Viking Therapeutics hits enrollment milestones for its obesity therapy, hires a top commercial leader, and earns strong analyst support, positioning for future regulatory progress and potential upside.

Viking Therapeutics’ dual‑delivery obesity drug VK 2735 hits Phase III milestones; upcoming J.P. Morgan presentation and VANQUISH‑2 data could boost investor confidence and share price.

Viking Therapeutics (VKTX) hits Phase‑3 enrollment for obesity drug VK2735, backed by strong cash reserves and investor optimism amid potential FDA pathway changes.

Viking Therapeutics’ struggle: declining stock, negative P/E, and unmet profitability targets in biotech, raising questions about its future in metabolic & endocrine therapy.

Viking Therapeutics, Inc. is a leading biopharmaceutical company making significant strides in developing innovative therapeutics for metabolic and endocrine disorders, with a substantial market presence and a robust pipeline of potential treatments.